In addition, several other PSMA-targeted metal nanoparticle systems, such as 177Lu-labeled lutetium oxide (Lu2O3) NPs [43,44] and 223Ra-labeled NaA zeolite NPs [45,46], have been developed and evaluated to treat prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.